AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18573983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fee per sealant treatment
Number of subjects: 2833
Study 18573983 — intervention group
Group type: EXPERIMENTAL
Intervention: Education in evidence-based practice
Number of subjects: 2833
Study 18573983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fee plus education
Number of subjects: 2833
Study 18573983 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2833
Study 15042614 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (60 mg)
Number of subjects: 76
Study 15042614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 11399692 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial diagnosis of COPD based on hypothetical case presentation
Number of subjects: 192
Study 11399692 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of COPD after spirometry
Number of subjects: 192
Study 11399692 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of COPD after oral steroid trial
Number of subjects: 192
Study 11399692 — intervention group
Group type: EXPERIMENTAL
Intervention: Request for spirometry after initial presentation
Number of subjects: 192
Study 9240873 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified formula (12.3 mg/l iron)
Number of subjects: 406
Study 9240873 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fortified formula (1.4 mg/l iron)
Number of subjects: 406
Study 9240873 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 406
Study 8494130 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg wrapping with elasticated Esmarch bandages
Number of subjects: 97
Study 8494130 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg elevation alone
Number of subjects: 97
Study 8494130 — intervention group
Group type: COMPARATOR
Intervention: Control group (neither leg elevation nor wrapping)
Number of subjects: 97
Study 3327673 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 118
Study 3327673 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 118
Study 3327673 — intervention group
Group type: COMPARATOR
Intervention: Minoxidil
Number of subjects: 118
Study 30064264 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric interdisciplinary home rehabilitation (n=106)
Number of subjects: 205
Study 30064264 — intervention group
Group type: COMPARATOR
Intervention: Conventional geriatric care and rehabilitation (n=93)
Number of subjects: 205
Study 29946728 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib 5 mg orally once daily for 21 days followed by 7 days off in 28-day cycles (n=278)
Number of subjects: 416
Study 29946728 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=138)
Number of subjects: 416
Study 29946728 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib 5 mg
Number of subjects: 416
Study 29946728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 26745852 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 1776
Study 26745852 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 1776
Study 24974317 — intervention group
Group type: EXPERIMENTAL
Intervention: SES-related risk
Number of subjects: 627
Study 22824596 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate
Number of subjects: 140
Study 22824596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac
Number of subjects: 140
Study 22824596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Number of subjects: 140
Study 22824596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 20639271 — intervention group
Group type: EXPERIMENTAL
Intervention: Avonex 1 x 30 microg/week (IFN‐30)
Number of subjects: 50
Study 20639271 — intervention group
Group type: EXPERIMENTAL
Intervention: Avonex 1 x 60 microg/week (IFN‐60)
Number of subjects: 50
Study 20639271 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a treatment
Number of subjects: 50
Study 20639271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17998225 — intervention group
Group type: EXPERIMENTAL
Intervention: 300,000 IU intramuscular vitamin D2 injection
Number of subjects: 9440
Study 16311455 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanic membrane displacement (TMD) measurements using the Marchbanks measurement system analyser
Number of subjects: 225
Study 16311455 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive measurements of ICP
Number of subjects: 225
Study 16311455 — intervention group
Group type: COMPARATOR
Intervention: Control group of volunteers
Number of subjects: 225
Study 12487015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 142
Study 9788030 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 42
Study 9788030 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 42
Study 7808602 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg tissue-type plasminogen activator (TD-2061), three times daily for 5 days
Number of subjects: 53
Study 7808602 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg tissue-type plasminogen activator (TD-2061), three times daily for 5 days
Number of subjects: 53
Study 7808602 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg tissue-type plasminogen activator (TD-2061), three times daily for 5 days
Number of subjects: 53
Study 7808602 — intervention group
Group type: EXPERIMENTAL
Intervention: All dose groups (0.1 mg, 0.2 mg, 0.4 mg)
Number of subjects: 53
Study 2684309 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 82
Study 2684309 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 82
Study 2684309 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate-cyclosporine
Number of subjects: 82
Study 4712485 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory perceptual tasks
Number of subjects: 0
Study 31563589 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute c‐ICA stenting
Number of subjects: 24
Study 31563589 — intervention group
Group type: COMPARATOR
Intervention: No stenting
Number of subjects: 24
Study 30633414 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of dissection (higher number of dissected facial nerve branches)
Number of subjects: 148
Study 30633414 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative follow-up (scar appearance and substance loss)
Number of subjects: 148
Study 28647161 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led pathway
Number of subjects: 506
Study 28647161 — intervention group
Group type: COMPARATOR
Intervention: Conventional pathway
Number of subjects: 506
Study 25865175 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent self-weighing (daily or several times per week)
Number of subjects: 583
Study 23332012 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8(+)CD38(+)HLA-DR(+) T-cell activation
Number of subjects: 60
Study 23332012 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6
Number of subjects: 60
Study 23332012 — intervention group
Group type: EXPERIMENTAL
Intervention: soluble vascular cell adhesion molecule (sVCAM)
Number of subjects: 60
Study 23332012 — intervention group
Group type: EXPERIMENTAL
Intervention: tumour necrosis factor-α receptor-I (TNFR-I)
Number of subjects: 60
Study 23332012 — intervention group
Group type: EXPERIMENTAL
Intervention: fibrinogen
Number of subjects: 60
Study 23332012 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and CD8(+)CD38(+)HLA-DR(+) percentage
Number of subjects: 60
Study 23332012 — intervention group
Group type: EXPERIMENTAL
Intervention: sVCAM concentration
Number of subjects: 60
Study 21406510 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy
Number of subjects: 12507
Study 21406510 — intervention group
Group type: COMPARATOR
Intervention: As-needed LABA
Number of subjects: 12507
Study 18506620 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel/capecitabine (TX)
Number of subjects: 122
Study 18506620 — intervention group
Group type: EXPERIMENTAL
Intervention: doxorubicin/cyclophosphamide (AC) followed by paclitaxel (T)
Number of subjects: 122
Study 18506620 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/doxorubicin/cyclophosphamide (FAC)
Number of subjects: 122
Study 17204967 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient sprinkles (MMN) containing iron 12.5 mg + folic acid 150 microg + zinc 5 mg + vitamins A, C and D3
Number of subjects: 204
Study 17204967 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron/folate sprinkles (iron 12.5 mg + folic acid 150 microg)
Number of subjects: 204
Study 17204967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 15133373 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation response (RR) training
Number of subjects: 57
Study 15133373 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac education
Number of subjects: 57
Study 15133373 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study 15171476 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of blood volume changes during hemodialysis using an online blood volume monitor (Hemoscan)
Number of subjects: 12
Study 15171476 — intervention group
Group type: EXPERIMENTAL
Intervention: deltaBV/UF ratio
Number of subjects: 12
Study 15171476 — intervention group
Group type: EXPERIMENTAL
Intervention: deltaBV/UF ratio of less than 2.6%/L
Number of subjects: 12
Study 11369149 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-treatment group (n=123)
Number of subjects: 245
Study 11369149 — intervention group
Group type: COMPARATOR
Intervention: Active control group (n=122)
Number of subjects: 245
Study 11369149 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (self-treatment and active control)
Number of subjects: 245
Study 9260599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg orally twice a day
Number of subjects: 406
Study 9260599 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron suppository 16 mg once daily
Number of subjects: 406
Study 9260599 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 406
Study 8317686 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 60
Study 8317686 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% and prilocaine 2% in a 1:1 ratio
Number of subjects: 60
Study 3551127 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (Trandate; Allen & Hanburys)
Number of subjects: 20
Study 3551127 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine (Nepresol; Ciba)
Number of subjects: 20
Study 29596123 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track recovery protocol (FT), n = 32
Number of subjects: 62
Study 29596123 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol (CON), n = 30
Number of subjects: 62
Study 27836132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprocedural Thrombotic Events (IPTEs)
Number of subjects: 6591
Study 27836132 — intervention group
Group type: COMPARATOR
Intervention: Control (no IPTE)
Number of subjects: 6591
Study 24754606 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile epidural analgesia
Number of subjects: 0
Study 24754606 — intervention group
Group type: COMPARATOR
Intervention: No mobile epidural analgesia
Number of subjects: 0
Study 23572341 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% inhaled xenon for 24 h combined with 72 h of moderate systemic hypothermia
Number of subjects: 14
Study 20529340 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and diet intervention
Number of subjects: 597
Study 19066383 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery incentive program
Number of subjects: 57
Study 19066383 — intervention group
Group type: EXPERIMENTAL
Intervention: Deposit contract
Number of subjects: 57
Study 19066383 — intervention group
Group type: COMPARATOR
Intervention: Control group (monthly weigh-ins)
Number of subjects: 57
Study 16368312 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥ 30 kg/m2)
Number of subjects: 2082
Study 14651695 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing training (30 minutes per day, 6 days per week for 8 weeks)
Number of subjects: 61
Study 14651695 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 61
Study 10552108 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8893656 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine (mini doses)
Number of subjects: 6
Study 8893656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1379970 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172
Number of subjects: 0
Study 1379970 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 6391442 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betaxolol hydrochloride 0.5% every 12 hours
Number of subjects: 0
Study 6391442 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betaxolol hydrochloride 0.5% every 12 hours with oral acetazolamide 500 mg every 12 hours
Number of subjects: 0
Study 6391442 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide 500 mg every 12 hours
Number of subjects: 0
Study 6391442 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide 500 mg every 12 hours with topical betaxolol
Number of subjects: 0
Study 31733455 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Adenosyl-Methionine (SAMe) 3,200 mg/day
Number of subjects: 65
Study 31733455 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day
Number of subjects: 65
Study 31733455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 30201225 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU bolus followed by 4000 IU cholecalciferol/day for 16 weeks)
Number of subjects: 65
Study 30201225 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 65
Study 30201225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 28746065 — intervention group
Group type: EXPERIMENTAL
Intervention: PENS T6 with 1200 kcal/d diet
Number of subjects: 200
Study 28746065 — intervention group
Group type: EXPERIMENTAL
Intervention: PENS T6 with normocaloric diet
Number of subjects: 200
Study 28746065 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical neurostimulation of T11-T12 with 1200 kcal/d diet (placebo)
Number of subjects: 200
Study 28746065 — intervention group
Group type: COMPARATOR
Intervention: Only 1200 kcal/d diet
Number of subjects: 200
Study 26575249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring (IONM)
Number of subjects: 50
Study 26575249 — intervention group
Group type: COMPARATOR
Intervention: Non-intraoperative neuromonitoring (non-IONM)
Number of subjects: 50
Study 23910908 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric acid suppressive medications (AS)
Number of subjects: 0
Study 21477068 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (6 mg)
Number of subjects: 12
Study 21477068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19678813 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐ASA‐MMX (2.4 g/day, once daily)
Number of subjects: 331
Study 19678813 — intervention group
Group type: COMPARATOR
Intervention: Asacol (2.4 g/day, twice daily)
Number of subjects: 331
Study 17197641 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg/day; NSAID)
Number of subjects: 10
Study 17197641 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 10
Study 14679295 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0
Study 14679295 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine
Number of subjects: 0
Study 12010161 — intervention group
Group type: EXPERIMENTAL
Intervention: Frios bone trap
Number of subjects: 38
Study 12010161 — intervention group
Group type: COMPARATOR
Intervention: Osseous Coagulum Trap
Number of subjects: 38
Study 9866959 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone fenestration with mallet and gouge without odontotomy
Number of subjects: 100
Study 9866959 — intervention group
Group type: COMPARATOR
Intervention: Odontotomy preceding tooth excision
Number of subjects: 100
Study 7840355 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic instrument developed for the DSM-IV field trial
Number of subjects: 50
Study 7840355 — intervention group
Group type: EXPERIMENTAL
Intervention: Royal Park Multidiagnostic Instrument for Psychosis
Number of subjects: 50
Study 7840355 — intervention group
Group type: EXPERIMENTAL
Intervention: Munich Diagnostic Checklists
Number of subjects: 50
Study 7840355 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus DSM-III-R diagnosis by expert clinician researchers
Number of subjects: 50
Study 2171595 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiotherapy (40 Gy in the chest tumour)
Number of subjects: 53
Study 350496 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (6 mg trimethoprim plus 30 mg sulphamethoxazole/kg)
Number of subjects: 105
Study 350496 — intervention group
Group type: COMPARATOR
Intervention: Streptomycin (50 mg/kg)
Number of subjects: 105
Study 350496 — intervention group
Group type: COMPARATOR
Intervention: Neomycin (50 mg/kg)
Number of subjects: 105
Study 7036289 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (chemotherapy, immunotherapy, and chemoimmunotherapy)
Number of subjects: 845
Study 7036289 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 845
Study 31058908 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based monitored exercise using a smart digital garment and wristband, with motivation and reinforcement via text messages.
Number of subjects: 0
Study 31058908 — intervention group
Group type: COMPARATOR
Intervention: Standard CR facility-based exercise.
Number of subjects: 0
Study 29412514 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Implemented Early Start Denver Model (P-ESDM) intervention for 26 weeks, 1.5 hours of parent coaching per week.
Number of subjects: 43
Study 29412514 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Implemented Early Start Denver Model (P-ESDM) intervention for 26 weeks.
Number of subjects: 43
Study 29412514 — intervention group
Group type: COMPARATOR
Intervention: Community interventions available from communities for 26 weeks.
Number of subjects: 43
Study 26558446 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellofemoral bracing
Number of subjects: 204
Study 26558446 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibiofemoral bracing
Number of subjects: 204
Study 26558446 — intervention group
Group type: COMPARATOR
Intervention: No bracing
Number of subjects: 204
Study 24911220 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylene Glycol-Free melphalan (PGF-Mel)
Number of subjects: 24
Study 24911220 — intervention group
Group type: COMPARATOR
Intervention: Alkeran
Number of subjects: 24
Study 22315328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1 ml kg(‐1) 0.2% or 0.35% at an injection speed of 0.25 ml s(‐1)
Number of subjects: 50
Study 22315328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1 ml kg(‐1) 0.2% or 0.35% at an injection speed of 0.5 ml s(‐1)
Number of subjects: 50
Study 19822404 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium patch
Number of subjects: 153
Study 19822404 — intervention group
Group type: COMPARATOR
Intervention: Control (menthol) patch
Number of subjects: 153
Study 17601378 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ATRA therapy for 62+/−5 months
Number of subjects: 75
Study 17601378 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ATRA therapy for 62+/−5 months among patients with genotype II
Number of subjects: 75
Study 17601378 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ATRA therapy
Number of subjects: 75
Study 17601378 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 75
Study 15298525 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group intervention for grandparents
Number of subjects: 97
Study 15298525 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 97
Study 11519502 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (two 2-g doses, 48 hours apart, repeated at 24 to 29 weeks)
Number of subjects: 617
Study 11519502 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two doses, 48 hours apart, repeated at 24 to 29 weeks)
Number of subjects: 617
Study 9285463 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg/day) and levodopa
Number of subjects: 16
Study 9285463 — intervention group
Group type: COMPARATOR
Intervention: Levodopa alone
Number of subjects: 16
Study 9285463 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of selegiline
Number of subjects: 16
Study 8289134 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg daily oral doses
Number of subjects: 14
Study 8289134 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg daily oral doses
Number of subjects: 14
Study 8289134 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg daily oral doses
Number of subjects: 14
Study 8289134 — intervention group
Group type: COMPARATOR
Intervention: Crossover design with washout periods of 7 days
Number of subjects: 14
Study 2951449 — intervention group
Group type: EXPERIMENTAL
Intervention: rHBsAg vaccine (20 micrograms intramuscular dose)
Number of subjects: 40
Study 2951449 — intervention group
Group type: COMPARATOR
Intervention: HEPTAVAX-B vaccine (plasma-derived)
Number of subjects: 40
Study 28294694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral Low-Level Laser Therapy (LLLT)
Number of subjects: 60
Study 28294694 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Low-Level Laser Therapy (LLLT)
Number of subjects: 60
Study 28294694 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonactive laser)
Number of subjects: 60
Study 28294694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral LLLT
Number of subjects: 60